Antivirals already on the market and expertise gained from the SARS and MERS outbreaks are gaining momentum as the most effective way to combat the coronavirus outbreak. SARS-CoV-2 has caused considerable mortality due to respiratory failure, highlighting the immediate need for successful therapies as well as the long-term need for antivirals to combat potential emergent mutants of coronaviruses. There are constant viral mutations are being observed due to which world is experiencing different waves of SARS-CoV-2. If our understanding of the virology and clinical presentation of COVID-19 grows, so does the pool of possible pharmacological targets. In COVID-19, the difficulties of proper analysis of current pre-clinical/clinical data as well as the creation of new evidence concerning drug repurposing will be crucial. The current manuscript aims to evaluate the repurposing of an anti-HIV drug Darunavir Ethanolate in COVID-19 treatment with in silico study and we discuss the therapeutic progress of Darunavir Etanolate, to prevent SARS-CoV-2 replication, which supports its clinical assessment for COVID-19 therapy.
Purpose Cardiac hypertrophy is a key contributor to adverse remodeling and the progression of cardiovascular diseases. Ponatinib, a multi-targeted tyrosine kinase inhibitor approved for oncology, has been shown to inhibit growth factor signaling pathways implicated in hypertrophy. This study aimed to investigate the molecular targets of Ponatinib and evaluate its effects on cardiac hypertrophy. Methods Network pharmacology was used to identify Ponatinib-associated targets and their overlap with cardiac disease-related genes. Protein–protein interaction (PPI) analysis, Gene Ontology (GO) analysis, and KEGG pathway enrichment analysis were performed to identify key pathways. Molecular docking assessed binding affinities with selected targets. In vitro validation was conducted in H9C2 (2–1) cells subjected to high-salt-induced hypertrophy, in which cell viability, cell size, and α-smooth muscle actin (α-SMA) levels were measured. Results Twenty-four overlapping targets were identified, with EGFR, MAPK8, MAP3K7, JAK2, and PDGFRB as key regulators enriched in MAPK and PI3K-Akt pathways. Docking showed strong binding affinities, particularly with PDGFRB and JAK2. In vitro, Ponatinib (0.25 µM) significantly reduced cardiomyocyte hypertrophy while maintaining cell viability. However, no significant reduction in α-SMA levels was observed. Conclusion Ponatinib attenuates cardiac hypertrophy through multi-target modulation of growth factor signaling pathways. Further studies are needed to explore its role in cardiac hypertrophy.